LGALS3 signaling and macrophage ferroptosis in steatohepatitis

Table 1 Translational deliverables for evaluating LGALS3-TRAF6-GPX4 axis in metabolic dysfunction-associated steatohepatitis

Domain	Specimen/system	Assay/readout	Translational purpose	Decision impact
Disease staging and baseline risk	Serum/plasma; elastography platform	FIB-4; ELF where available; VCTE; FAST or other validated composite NITs	Define baseline disease severity and enrich for patients with active steatohepatitis and clinically meaningful fibrosis	Trial enrichment; subgroup definition; baseline comparability
Exploratory target engagement	Liver tissue; serum/plasma; macrophage assay systems	Liver LGALS3/TRAF6/GPX4 by immunohistochemistry or immunoblotting; circulating LGALS3; oxidative/iron-stress readouts such as lipid peroxidation and iron-related indices	Determine whether the proposed axis is modulated in vivo or ex vivo after intervention	Proof-of-mechanism; early pharmacodynamic assessment
Potency definition	Standardized macrophage-based bioassay	LGALS3/TRAF6 pathway activity under defined stimulation; GPX4-related redox and iron-handling readouts; predefined acceptance range for active batches	Define what constitutes an active and comparable batch of the final formulation	Batch release; comparability across production lots and study sites
Chemistry and quality control	Raw materials and finished product	Botanical authentication; chromatographic fingerprinting; prioritized marker/Q-marker panel; contaminant and stability testing	Link chemical consistency to biological consistency and manufacturing control	Regulatory readiness; manufacturing scalability; batch-to-batch reproducibility
Human relevance and model bridging	Primary human Kupffer cells; precision-cut liver slices; metabolically relevant animal models	Directional validation of axis modulation across human-relevant systems and obesity-linked disease models	Reduce the risk that the mechanism is restricted to a single mouse model or immortalized macrophage line	External validity; confidence for clinical translation
Clinical positioning and safety	Clinical development plan; medication-exposure context	Predefined add-on/sequence/combination hypothesis; herb-drug interaction assessment; liver-specific safety monitoring	Clarify where the intervention could fit in the current MASH treatment landscape and whether chronic use is feasible	Clinical adoption pathway; risk mitigation; go/no-go decisions
Durability and fibrosis-linked benefit	Longitudinal animal studies and, later, clinical follow-up datasets	Repeated histology where appropriate; fibrosis-related NIT trajectories; relapse/stressor robustness	Distinguish transient biochemical improvement from sustained fibrosis-relevant benefit	Phase-transition value; long-term development relevance

ELF: Enhanced liver fibrosis test; FAST: FibroScan-aspartate aminotransferase score; FIB-4: Fibrosis-4; NIT: Noninvasive test; MASH: Metabolic dysfunction-associated steatohepatitis; Q-marker: Quality marker; VCTE: Vibration-controlled transient elastography.

Table 2 Evidence status and next-step validation of the proposed LGALS3-TRAF6-GPX4 framework

Domain/claim	Current support	Key gap	Priority next step	Translational impact
QWZG efficacy in experimental MASH	Improved histology, fibrosis-associated readouts, and oxidative/iron-stress indices in CDAHFD	Generalizability to obesity-linked disease settings is unknown	Validate efficacy and axis modulation in at least one obesity-associated model	External validity
LGALS3 as an upstream node	Macrophage-associated amplifier supported by the featured study and prior liver disease literature	Driver vs correlated marker remains unresolved in vivo	Myeloid/Kupffer cell-focused LGALS3 perturbation with rescue design	Target nomination
TRAF6-GPX4 linkage	TRAF6 inhibition supports directionality; external studies provide biochemical precedent	Direct regulation in hepatic macrophages is unproven	Cell-specific Traf6 manipulation plus GPX4 rescue or depletion	Mechanistic confidence
Macrophage ferroptosis as a disease layer	Ferroptosis is supported as an injury amplifier; Kupffer cell ferroptosis has experimental support	Dominant pathogenic cell compartment remains uncertain	Compare hepatocyte and macrophage ferroptosis readouts across models and time points	Actionable cell context
Kupffer cell necessity	Macrophage-line and whole-liver data are consistent with involvement	In vivo necessity is not established	Primary Kupffer cell validation and myeloid-compartment necessity testing	From plausibility to causality
Human relevance	The framework is biologically coherent and testable in human-oriented systems	Primary human Kupffer cell or PCLS confirmation is lacking	Validate in primary human Kupffer cells and/or precision-cut liver slices	Translational confidence
Formula-to-axis specificity	Pathway association is shown after QWZG exposure	Active constituents, direct targets, and composition-function linkage remain undefined	Potency-linked constituent prioritization and Q-marker construction	CMC readiness
Clinical development readiness	The axis offers an exploratory pharmacodynamic framework	No validated thresholds, positioning strategy, or interaction package	Develop exploratory biomarker assays plus add-on/sequence and safety plans	Clinical positioning

CDAHFD: Choline-deficient, L-amino acid-defined high-fat diet; CMC: Chemistry, manufacturing, and controls; MASH: Metabolic dysfunction-associated steatohepatitis; PCLS: Precision-cut liver slices; Q-marker: Quality marker.